2026.05.06
On May 6, 2026, Suzhou Synthera Biotech Co., Ltd. (Synthera Biotech) announced that it had entered into an exclusive global licensing agreement (excluding mainland China, Hong Kong, Maca, and Taiwan) with GlaxoSmithKline (GSK) for SA030.
SA030 is a potential first-in-class, long-acting small interfering RNA (siRNA) oligonucleotide currently in development for the treatment of metabolic and cardiovascular diseases. SA030 recently entered Phase I clinical trials, targeting activin receptor-like kinase 7 (ALK7), an established therapeutic mechanism for cardiometabolic diseases. Given the unresolved cardiometabolic risks in various chronic diseases, this project holds significant clinical and market potential.
GSK will pay an upfront fee and future milestone payments based on successful development, registration and commercialization, with the total amount reaching up to USD 1.005 billion. GSK will also pay tiered royalties on the global net sales of the product (excluding mainland China, Hong Kong, Macau and Taiwan).
Synthera Biotech will lead the clinical development of SA030 until the completion of the Phase I clinical trials. Afterward, GSK will assume responsibilities for the development, regulatory submissions and commercialization outside mainland China, Hong Kong, Macau and Taiwan.
JunHe was entrusted by Synthera Biotech to review, amend and negotiate the agreement for this project. JunHe's team earned the trust and recognition of the client with its consistently efficient, rigorous work style and meticulous, dedicated service attitude.
The lead partner for this project was ZHAO, Hao (Gerry).
